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Background: Pathological effects of cardiovascular risk factors may be mediated by immune responses. Smoking is a known risk factor for 
cardiovascular disease and leads to an increase in cardiovascular events. We previously developed a 5 gene blood-based gene-expression score 
(GES), measured by RT-PCR, that reflects response to smoking and is highly predictive of self-reported smoking status. We asked whether this GES 
can predict future revascularizations (PCI/CABG) or major adverse cardiovascular events (MACE).
methods: The GES was measured on 845 subjects (43% male, average age 60 years) from PREDICT, a clinical trial designed to identify markers 
associated with coronary artery disease in patients clinically referred for invasive angiography (NCT 00500617) in which 1 year follow-up had 
been obtained. Events were defined as subjects with revascularization or MACE (stroke/transient ischemia attack, MI, or death) >30 days post-
baseline catheterization. Logistic regression was used to assess the association between events and GES, using the GES both as a continuous and 
dichotomous predictor variable.
results: An event rate of 1.7% was observed in the cohort (8 MACE, 6 revascularizations). GES was significantly associated with revascularization 
and MACE in both the continuous and dichotomous models (p < 0.001, both models); the GES remained significantly associated with MACE alone (p 
= 0.008, p = 0.016 respectively). Using a 50% probability cut-off, the GES showed a specificity of 0.805, a sensitivity of 0.423, and an AUC of 0.627. 
Furthermore, the GES remained significant when self-reported smoking status was included in the continuous model (p = 0.047).
conclusion: The GES for smoking status was significantly associated with an increased likelihood of non-baseline revascularization and 
MACE. Combining the GES with other expression scores or biomarkers may provide an improved method for identifying patients at risk for future 
revascularizations or MACE.
